Virbac announces Giovanni Abruzzini’s appointment as president and CEO of Virbac North America, effective March 27, 2023. His main mission is to lead and develop all North American Virbac activities, in line with our Group’s global strategy. 

2022 current operating income on the rise at +8.3%, reflecting the momentum of our business over the year in a slowing market

On February 21, our farm animals team organized a webinar attended by nearly 900 veterinarians from all over the world. The objective? To present our new Smart DCT tool, which allows a better assessment of the infectious pressure in dairy herds during the dry period. This action aims at supporting better adapted treatments and a more responsible use of antibiotics.

Rotavirus is one of the main agents causing diarrhea in piglets¹. Since December 2022, our teams have been providing industry professionals in France and Germany with the very first rotavirus vaccine registered for pigs, enabling the immunization of newborn piglets via their mother’s colostrum.

Annual revenue growth of +9.6% at comparable exchange rates and scope (+14.3% at real rates), driven by exceptional business activity in the fourth quarter

Discover the video on the 2023 wishes of Sébastien Huron to all the teams in the world.

In February 2022, Virbac Colombia celebrated its 20 years of commitment to animal health with all its employees and then, on November 4th, with the partners of its Colombian subsidiary and the Andean region, Sandrine Brunel as representative of the head office, the LatAm committee and the entire management team of Virbac Colombia & Andes.

On November 30, Virbac inaugurated its new R&D center in Pingtung Agricultural Biotechnology Park (PABP) in Taiwan which marked an important milestone for Virbac R&D.

Between May and June 2022, some thirty employees from each of our subsidiaries met for international Great Place To Work^® workshops to discuss the local employee experience and best practices within certified companies. 

Mobility issues are common in dogs and can greatly impact their quality of life. To keep their joints healthy, our teams have developed MOVOFLEX^®, a new joint supplement combining five ingredients, including eggshell membrane. It includes an innovative formulation, gradually available in Europe from November 2022, for a complete action that significantly contributes to improving the animal's mobility.

To meet the global needs for pet vaccines, including those of certain countries such as China, a new aseptic filling line dedicated to liquid vaccines and diluents has been installed at VB8, a building dedicated to the manufacture of sterile forms.

Pet reproduction control habits vary from one country to another. In Latin America, 60 to 70% of male dogs are not castrated, often because dog owners are concerned about the surgery and its possible consequences. Alternative solutions exist and are available in a growing number of countries in this area. Danilo Martinez, our Latin America pet marketing manager at Virbac, tells us more.

Since this month of October, we are an official sponsor of the World Small Animal Veterinary’s Reproduction Control Committee. Our common goal? To promote, on a worldwide level, the best veterinary practices in this key field for the health of cats and dogs. 

Revenue growth at end of September at +7.7% at comparable exchange rates and perimeter (+12.7% at actual rates)

To meet the growing demand for our petfood range, we will build a new production site in Nîmes (Gard, France). This evolving site will integrate all the steps from raw materials to the finished product.

Virbac announces the appointment of Sophie Favini as the Group's new head of Global Commercial Operations. Previously the executive vice-president of Virbac's USA Commercial Operations, Sophie Favini, based in Westlake, Texas, replaces Hubert Trentesaux who has retired.

Increase in operating income in the first half of 2022 reflecting the dynamism of our business

In September 2022, our teams have answered to advance preventive medicine at the largest world congress of buiatrics.

Growth in revenue in the first half of 2022 of +12.0% at comparable exchange rates (+16.4% at real rates), driven by good performance in all areas

We continue to increase our footprint in the livestock market and are proud to announce the launch of TENOTRYL^TM (enrofloxacin) injectable solution for use in cattle and swine. Our product was approved by the FDA on March 28th and will be available to those who care for animals beginning in July. TENOTRYL^TM (enrofloxacin) injectable solution comes in 100, 250 and 500 ml vials.

Although neutering of pets is sometimes essential, methods are evolving to meet new societal expectations. At Virbac, we offer the Suprelorin^® implant, a reversible medical neutering solution. Used since 2007 for male dogs, Suprelorin^® obtained on June 14, 2022, an extension of its marketing authorization in the European Union for use in male cats and prepubescent bitches. The extension of its application offers veterinarians new solutions to better adapt to the expectations of owners and the needs of their animals.

Oral health is essential to the overall health and quality of life of cats and dogs, and their owners have an active role to play in preventing dental disease. That is why we recently supported FECAVA's initiative: educational fact sheets to help veterinarians educate owners about the importance of their pets' oral health.

Limiting the use of treatments, in particular antibiotics, by supporting the body's natural processes: this is one of the objectives of micronutrition or trace mineral supplementation. On the occasion of our 30 years of expertise in this field, let's take a look at what has become one of the pillars of our approach to cattle health.

In June 2022, Virbac decided to deploy the Learning part in Workday at group level, an agile solution that also meets local requirements. 

In June, join us at the IPVS World Congress in Brazil. We are sharing with swine professionals the latest scientific data on porcine circovirus as well as our preventive approach to swine health, which emphasizes vaccination tools and updated technology. 

Our leptospirosis vaccine production capacity will be quadrupled in 2023 thanks to the technological transfer to a high-tech unit!

Deployment of the industrial operations transformation program on June 6, 2022 in North America.

On the occasion of the Chinese launch of our key anti-parasite products, Milpro^® and Effipro Duo^®, Virbac offers an innovative approach based on personalized protocol.

Very strong growth in revenue in the first quarter of 2022 of +16.2% at comparable exchange rates (+19.3% at real rates), driven by good performance in all areas

With a world population that could reach 9 billion people by 2030, we at Virbac anticipate the growing importance of aquaculture as an essential source of protein for humans in the years to come. We have been present for several years in all key segments of the sector, in warm and cold waters, and in 2022 we will continue our actions to help farmers to meet this growing demand in a sustainable way. Our global approach combines solutions focusing on prevention and services to implement them effectively.

2021 operating profit from ordinary activities showed very strong growth, reflecting the excellent dynamism of our business in a rapidly growing market

In order to promote the urinary health of cats, our teams have developed two new wet foods. They will soon be available to cat owners throughout Europe, as an addition to our Veterinary HPM^® dry food range.

Since the beginning of the war in Ukraine, our teams have implemented various initiatives to help those facing these tragic circumstances.

This new award honors our sustainable development approach.

United States: Virbac enters the pet nutrition market with the launch of a product range for neutered and spayed dogs and cats.

Details of the results of the new CSR ranking.

Exceptional growth in annual revenue of +18.4% at comparable exchange rates and scope (+14.9% at constant rates and real scope), driven by remarkable performance in a very buoyant market

Construction of a global center of excellence for biological products has begun in Carros.

Discover the video on the 2022 wishes of Sébastien Huron, chief executive officer.

We are implementing an eco-responsible approach to supplies and flows.

Advancing animal health. This is what mobilized our teams on a daily basis throughout 2021. Discover the panorama of the year in a 1 minute video!

Virbac's first steps into the U.S. food producing animal market.

Video retrospective of the first Virbac days dedicated to safety in France.

Virbac announces the acquisition of the remaining minority shares of the Centrovet group.

Although neutering of pets is sometimes essential, methods are evolving to meet new societal expectations. At Virbac, we have been offering a reversible alternative to surgical castration for several years. In 2021, we are continuing our efforts to make this alternative available to more and more dog owners throughout the world and to support professionals in adopting this solution that is more respectful of the animal's physical integrity.

Excellent revenue growth of 21.2% at the end of September at comparable exchange rates and scope (+16.4% at constant rates and real scope), driven by a very solid third-quarter performance again in all areas

A nice evolution of our new worldwide internal opinion survey.

Virbac and Jectas Innovators are proud to announce the signature of a collaborative agreement for the development of animal health vaccine(s).

Significant increase in operating profit from ordinary activities for the first half of 2021 due to the sound market performance and dynamism of our business

Virbac announces the acquisition of additional shares in the Centrovet group.

Installation of two new packaging lines for our petfood.

July 26, visit to Carros of the prefect for the nice region and the Public accounts deputy minister.

Exceptional increase in revenue in the first half of 2021, with +21.3% at comparable exchange rates and scope (+14% at constant exchange rates and actual scope), driven by very solid performance in all areas and good market dynamics

New CSR indicators and GRI compliance for 10 years 

As part of its 2030 vision, Virbac completed the acquisition of iVet LLC, a specialty petfood company. This acquisition, in addition to the portfolio of products, will bring us expertise in distribution, logistics and e-commerce which are part of the key to the success of our petfood ambition in the USA.

2021 Outlook

Virbac, today announced the successful completion of its divestment of the production plant located in Magny-en-Vexin to FC France SAS, a subsidiary of Friulchem SpA and Finest SpA. 

As a non-voting advisor, his role will be mainly to support the good governance of our company by strengthening the complementarity of the skills of the board of directors.

Since 2017, we have been offering European veterinarians Speed Reader^TM, an in-clinic analyzer for the determination of blood markers and a series of biomarker tests. This year, we are enriching our in-clinic diagnostic solutions with a software that allows all analyses to be collected on a single digital platform, for optimal monitoring of each animal.

The "virbac.signalement.net" tool made available to all teams worldwide.

As part of its 2030 vision, Virbac sells the ownership and activity of the Magny-en-Vexin industrial site to Friulchem, a CMO (Contract manufacturing organization) partner of Virbac for more than twenty years and specialized among others in the production of antibiotics. Following the sharp decline in demand in recent years for the type of products manufactured in Magny-en-Vexin, this option will preserve employment, the competitiveness of the site and products.

Agreement signed for the distribution in Europe of a new weekly anti-inflammatory drug.

Respiratory diseases are one of the most common pathologies affecting cattle and swine: all over the world, they are responsible for a high mortality rate in herds and significant economic losses. At Virbac, we support a reasonable use of antibiotics by using new technologies to help veterinarians and farmers make the right treatment decision at the right time and improve dosage and traceability.

Very strong growth in revenue in the first quarter of 2021 at +22.6% at comparable exchange rates and scope (+12.3% at constant rates), driven by very solid performance in all areas
 

2020 current operating income showed strong growth (+37.6% at constant rates and scope), reflecting the excellent evolution of revenue (+5.7% at constant rates and scope) and a sharp decrease in expenses in the context of the Covid-19 crisis

Information following the approval of the European competition authorities

Find out the press release issued on February 23^rd.

Today, we are inaugurating our first research and development center dedicated to warm water aquaculture in the Dong Nai province in Vietnam. Aquaculture is a rapidly growing sector, particularly in Asia, and provides an answer to the problems of feeding a world population that could reach 9 billion people in 2030. True to our mission to work for animal health, we continue to invest in order to offer new solutions for more sustainable aquaculture.

We are improving our presence in the ranking of the 70 French companies with the best ratings in terms of social and environmental responsibility.

2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) 

Discover the press release issued on january 12^th

On November 16, 2020 the Food and Drug Administration (FDA) granted approval of our new treatment against canine skin tumors. With this approval, we bring U.S. veterinarians a true innovation in canine oncology and a new option to manage mast cells tumors, the most common skin cancer diagnosed in dogs.

Discover the video of Sébastien Huron, chief executive officer of the Virbac group, for the end of the year 2020.

Ensuring the safety of our employees and maintaining our business essential to the animals' health. These are the two major challenges met in 2020 facing an unprecedented health crisis. We would like to share with you the panorama of this exceptional year on video.

The longer life span of pets goes hand in hand with the increase in geriatric diseases, particularly the number of cancers being diagnosed. Since the beginning of 2020, we have been offering European veterinarians an innovative treatment solution that specifically targets mastocytomas, the most common form of canine skin cancer.

Revenue grew +6.8% at constant exchange rates and scope at the end of September 2020 (+5.6% at constant rates) thanks to solid third quarter performance

Virbac will change its governance at its shareholders' meeting on December 15

Full details of this new partnership can be found in the joint press release issued on September 15.  

Operating profit from ordinary activities up sharply for the first half of 2020 reflecting revenue resiliency and strong expenditure restraint during the Covid-19 crisis

Revenue grew by +5.0% at constant exchange rates in the first half of 2020 (+4.5% excluding Sentinel), impacted by a decline in the second quarter of the year

By 2 years of age, 70% of cats and 80% of dogs have some form of dental disease (Niemiec BA., 2008). Dental care prevention is key to avoid serious and painful disorders that can affect pets’ overall health and lifespan. Let's discover together in this video how we can improve our four-legged companions’ dental hygiene!

Virbac completes divestment of U.S. Rights to SENTINEL^® brands to MSD Animal Health

7.7 billion people on Earth, half live with pets. Every day, dogs and cats are exposed to unwanted parasites, vectors of various diseases that can affect their health and sometimes our own. We are all part of the same ecosystem. Protection against parasites is therefore a necessity that imposes to find the right balance between the health of animals, humans and their environment. That’s why our solutions allow veterinarians and owners to adapt protection to the specific parasite risk of each animal so that, all together, we can contribute to a responsible use of parasiticides.

In a growing number of countries, companion animals are considered to be sentient beings that are a part of the family. Although sterilization is sometimes necessary, the methods to manage dogs’ fertility and unwanted behaviours are changing to take societal expectations into consideration.

On April 24, more than 350 veterinarians and experts attended our first scientific summit dedicated to veterinary oncology. Thanks to this exclusive online event, European and North American practitioners have been able to discover the latest scientific data and a new treatment option of canine mast cell tumors.

Virbac to divest U.S. Rights to SENTINEL^® brands to MSD Animal Health

Since April 11, 2020, following an underground pipeline rupture, our Bio4 dog and cat vaccine production site has been shut down. We expect to resume operations in June, after a refurbishment allowing the resumption of manufacturing under GMP (Good manufacturing practice) rules.

2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying

Since the beginning of the coronavirus outbreak, numerous measures have been taken around the world to protect the health and safety of our employees and ensure the continuity of our commitment to animal health.

Today, more than ever, we are striving to make our animal health solutions even more accessible to veterinarians, farmers and animal owners around the world. This is why in 2019, we launched a pilot program in France to transform our industrial activities. A great adventure for our teams, who are mobilising all their know-how to continue to develop the Virbac production sites in terms of performance, safety and quality. Watch the 2019 achievements in video.

2019 operating profit from ordinary activities on the rise

Find out the press release dated March 9.

Neonatal gastroenteritis is the leading cause of calf mortality before the age of one month and causes significant losses to farmers. With our Calf Care Solutions program, we work with veterinarians and farmers to adopt a comprehensive calf health management approach that integrates diagnosis, prevention and care. Our goal is to share our tools and technical knowledge to more effectively manage on-farm diarrhea episodes through sustainable farming practices that respect animal welfare.

End of November, the Virbac teams shared for one day the groundbreaking ceremony of a new research & development center in Taiwan. This site will be dedicated to the support of aquaculture and swine farming activities in Asia.

Through its partnership with QBiotics, Virbac is providing veterinarians in Europe with a breakthrough injectable solution to treat mastocytoma in dogs. With this new treatment, the Group once again demonstrates its commitment and ability to offer innovative solutions for the advancement of veterinary science.

2019 annual revenue shows strong growth of +6.6% at constant exchange rates

Sébastien Huron, chairman of the executive board of the Virbac group, wishes a happy new year for 2020 through a video.

As part of the French Fab mission lead by the French public investment bank (Bpifrance), Virbac sponsors a support mission in 2019 for young French companies wishing to establish themselves in Mexico.

Behavior disorders and joint problems are common in dogs and can affect their quality of life and their relationship with humans. With multifunctional chews, pet owners now have an easy to give solution to support their pet’s overall health and wellness, while acting on their dental hygiene.

Today 25 to 40% of dogs are overweight or obese. This is true everywhere in the world, whatever the size or breed. Since obesity can have serious health consequences, Virbac offers, in partnership with an expert in dog activity, PitPat, a comprehensive program combining a healthy diet and the measurement of the dog's activity using a device placed on its collar. Find out more about this approach that helps improve the relationship between the owner and his pet by watching the video below.

Virbac has accepted Jean-Pierre Dick’s resignation from the executive board, effective November 14, 2019.

Today, farmers have to ensure optimal farming conditions both for the animal welfare and productivity. Yet, in the lifetime of an animal or during the production cycle, there are periods where induced oxidative stress is particularly intense. In such cases, farmers have to supplement animals with trace mineral elements. To learn more about micro-nutrition, click below to watch the video.

Solid +8.4% growth in revenue at constant exchange rates at the end of September, 2019

This year marks the 30^th year of Virbac’s iconic Latin American subsidiary, and they wished to celebrate the past thirty years of innovation and dedication to animal health along with their employees and customers on October 5, 2019. With a unique vision aligned to the Virbac Group’s values, the company has always taken its environmental impact and its social responsibility towards employees to heart.

Following the quarterly review of its indices, the Paris stock exchange operator, Euronext, includes Virbac in the CAC Mid 60 and SBF 120 as from 23 September.

Operating profit on the rise in the first half of 2019

A major concern for pet owners, bad breath can disrupt the close bond between pet and owner and signal deeper health issues. In 2019, for the first time ever in China, Virbac introduced dental care solutions that include FR3SH™ technology to target the oral and digestive causes of bad breath.

In early June, Virbac launched a digital program dedicated to all new employees. Objective: within the first weeks of their arrival, build a common foundation of knowledge about the Group, its operations and its corporate culture.

Virbac announces the arrival of Cyrille Petit as a member of the supervisory board as of June 18, 2019. In addition, on the audit committee he will replace Olivier Bohuon, who is also a member of the supervisory board.

2019 first half-year revenue grew by +6.6% at constant exchange rates

In Turkey, the prevalence of canine leishmaniosis can reach 25% in some regions, especially around the Mediterranean basin. To face this zoonosis that is currently under-diagnosed by veterinarians and misunderstood among Turkish owners, Virbac has made available, since March 2019, CANILEISH^®, the first veterinary vaccine to prevent this disease.

As part of its 2018 annual report, Virbac published its first non-financial performance statement in April. This document marks a new stage for the Group, who is reinforcing its commitments to sustainable development.

End of 2018, the Virbac Husbandry Club in Vietnam, which helps pig and poultry farmers tackle local animal health issues, celebrated 10 years of activity. This 10^th anniversary is a testament to the Group’s drive to carry out sustainable actions that promote improvement in farming conditions.

As part of its diversity policy, Virbac has been conducting concrete actions for the recruitment, better integration and job retention of workers with disabilities since 2014 in France.

2019 first quarter revenue rose by +10.9% at comparable exchange rates

Mid-March, Virbac was rewarded in the United Kingdom for its digital Veterinary HPM^™ campaign by the VMA (Veterinary marketing association), which annually celebrates the best marketing initiatives in the field of animal health.

Each year, the ADF Paris awards honor the packaging innovations of the global aerosol and dispensing industries. Last January, the Virbac Smart Cap "all-in-one", already awarded in 2018 by Pharmapack, received the prize for the best innovation in the "Pharmacy" category.

2018 operating profit from ordinary activities grew by 13.4%

At the end of 2018, Virbac launched an online campaign in North America encouraging owners to consult their veterinarian about their dog’s dental health. It included a humorous video broadcasted on social networks, featuring a rubber toy that hates being chewed by a dog with bad breath.

2018 annual revenue grew by +4.5% at constant exchange rates

Sébastien Huron, chairman of the executive board of the Virbac group, wishes all the best for 2019 through a video.

In 2018, several Virbac websites were revamped: new contents, new design, new functionalities… all these changes aim at creating a better user experience.

In August, the FDA approved the transfer of production to the Virbac St. Louis site (Missouri) of a parasiticide for dogs acquired by the company at the beginning of 2015. The complexity of the industrial extrusion process required all the skills and attention of the American subsidiary and the Group's Production/Quality teams for nearly three years.

Bad breath is a common complaint of dogs’ owners but it can also be a sign of periodontal or digestive issues that can be painful for the pet. Thanks to a new formula, the C.E.T^® VEGGIEDENT^® FR3SH^™ dental chews tackle the oral causes of bad breath and help to restore the animal's intestinal balance while freshening its breath. Available since 2018 in the United States, Canada, the United Kingdom, France, Spain and Japan, they will gradually be present around the world in 2019.

In 2018, Virbac is part of the Gaïa Index, which recommends the 70 French companies with the best ratings in terms of social and environmental responsibility among a panel of 230 firms. Virbac has made a significant improvement of 14 places in the overall ranking compared to 2017.

After a twenty-year presence in Turkey through a local distributor, Virbac is creating its 33^rd subsidiary there. The objective: closer proximity in order to better respond to the expectations of animal health players.

Revenue grew by +5.5% at constant exchange rates at the end of September 2018

Operating profit up sharply in the first half of 2018

Revenue grew by +4.3% at constant exchange rates in the second quarter of 2018

After five years of research and development, Virbac teams have developed Smart Cap, dedicated to extracting liquid products. This patented innovation benefitting animal health, which combines ergonomics and safety, was recognized in early 2018 with a Pharmapack Award.

Virbac United States announced that Eric Bonner has been named vice president of Industrial Operations.

One of the present challenges of swine producers is finding solutions that preserve farm productivity while reducing the use of antibiotics. In Europe, Latin America and Asia, Virbac is assisting veterinarians and farmers with technical solutions and on farm training that focus on prevention and are based on a good reproduction management.

2018 first quarter revenue rose by +3.3% at comparable exchange rates

Operating profit from ordinary activities 2017 comparable to 2016

Since 2017, Virbac has been offering veterinarians Speed Reader^TM, a blood marker dosage analyzer with a series of biomarker tests. Usable directly in-clinic, these newest additions to the diagnostic range facilitate screening of common diseases in cats and dogs and ensure better monitoring of the animal.

Maintaining good health and welfare of cows is central to Virbac's approach of dairy production. Virbac created a specific program for professionals of dairy farming called Target 150. This program aims at bringing global & integrated solutions and protocols for a better and more sustainable production of milk. Developed in close cooperation with worldwide known experts, Target 150 ™ encourages prevention and answers the main problematics of the 150 critical days of production cycle of the dairy cows. As an essential part of the program, the second Virbac Dairy Symposium was organized in September 2017 to contribute strengthening the skills of dairy farming professionals and prepare them to the emerging technologies of tomorrow.

Annual sales comparable to 2016 at constant exchange rates after strong fourth-quarter growth

For 2018, find out the video wishes from Sébastien Huron, new chairman of the executive board of the Virbac group.

Yesterday, Virbac’s supervisory board officially appointed Sébastien Huron as chairman of the Group’s executive board. Sébastien Huron succeeds Éric Marée, chairman of the executive board for the past 18 years, who has retired. 

In August 2017, Virbac was awarded pet owner favorite brand for cat health care by Goumin.com, the largest online Chinese pet owner community. 

By mutual agreement, Virbac and the other shareholders of Centrovet have decided to postpone the option to buy the Chilean aquaculture specialist for three years, under the same pricing conditions.

Two years after its launch, with a rating of 17.5/20, the VETERINARY HPM^® Adult with salmon neutered & entire cat is one of the ‘best choices’ amongst thirteen dry cat foods (kibbles) tested by the INC (Institut National de la Consommation [French National Institute for Consumer Affairs]). This rating makes up for several years of development.

The treatment of dogs infected with leishmaniosis has been authorized in Brazil since 2016. Thanks to its publicity campaigns and its treatment solution introduced in January 2017, Virbac is contributing to the fight against this disease which, on a world scale, touches about 1 million of humans. 

Virbac: quarterly sales affected by distributor destocking in the United States

VETERINARY HPM™ dietetic is a new generation of nutrition for cats and dogs with health problems, created by staying close to the nutritional requirements of carnivores, respecting the nutritional requirements of carnivores. These foods should be recommended by the veterinarian depending on the animal's health problem. A veterinarian's option should be sought before use. Available since spring 2017 in European veterinary clinics, the VETERINARY HPM™ dietetic range will also be launched in Latin America (Mexico, Costa Rica and Chile) by the end of the year.

On September 5, 2017, Virbac’s supervisory board co-opted Solène Madelpuech into the supervisory board as a new member. On the same day, Jeanine Dick, aged 81, announced her resignation. 

Virbac announces the appointment of Sophie Favini as executive vice-president of US commercial operations. Based in Fort-Worth (Texas), she is effective in her role since July 13, 2017. Sophie Favini is now in charge of leading, developing and overseeing all US Sales, Marketing and Technical Services functions in order to increase the business activity of the subsidiary.
Virbac also announces the appointment of Colin Meyers as vice-president of sales. These two appointments will help Virbac achieve a sustainable growth in the US. 

Slight increase in first half results

Whether in the meat or dairy industries, quality production requires animals that are healthy from birth onward! With this in mind, Virbac has been progressively rolling out a complete Calf health management program in Europe since 2016. 

Virbac: second quarter sales growth largely offsets the decline in the first quarter

Virbac has announced the supervisory board’s intention to appoint Sébastien Huron as chairman of Virbac’s executive board, as of next December, when the mandate of the current chairman of the executive board, Éric Marée, expires. 

Bio-Gene announces collaboration agreement with Virbac for development of FLAVOCIDE™ as an insect control agent in ruminants. 

In May 2016, European practitioners (France, UK and Austria) discovered Effipro^® Duo, a new parasiticide used to treat and prevent tick and flea infestations in dogs and cats. The advantages of this product described by the Global Marketing manager parasiticides.

Following the launch of the VETERINARY HPM™ physiological range in 2015, Virbac started from March 1^st the launch of VETERINARY HPM™ dietetic for dogs and cats in Europe. A complete range still close to the nutritional requirements of carnivores and associated to the "Veterinary global care", a new global nutritional approach.

The Virbac American subsidiary decided to gather its distribution operations in Hunt Midwest SubTropolis (Missouri). The new center should be operational until the end of the year.

First quarter 2017 sales down, strongly impacted by stock effects in the distribution in the United States

The product VETERINARY HPM^® Adult Small & Toy has received a rating of 16.4/20 from the independent French consumer association UFC-Que Choisir. The cited product has been qualified as one of the “best choices” amongst the twenty complete dog foods that were tested. 

Public-private transfer (TPP). Behind this acronym lies the possibility for French companies to develop partnerships with French and European public research organizations. This opportunity for innovation was seized on by Virbac in 2009 and presented by the public research partnerships manager. 

Strong rebound in profitability in 2016  

In September 2016, on the initiative of the IT department, e-visits first appeared amongst the sales force in France. The purpose: allow greater reactivity from regional technical managers to questions from veterinarians. Explanations on this European-scale project by the market manager for Virbac France.

At the end of September, 2016, all activity at the Mayas factory in Mexico was transferred to the new industrial site of Argo Navis. A look back on this major project and the challenges it presented with the Virbac Mexico Industrial director.

Annual sales growth of 4.5%, at constant exchange rates

Virbac announces that it has received from the Food and drug administration (FDA) a communication confirming the lifting of the Warning Letter received in December 2015 for its St. Louis production site (Missouri, USA).

Xavier Montat, general manager of Virbac Mexico since last year, announces the transfer of all production operations to the Argo Navis site in Guadalajara. This relocation marks the completion of the project launched in 2011 to support the strong growth of the Virbac Mexican subsidiary.

Sales grow by 3.2% at the end of September at constant rates

14 September 2015, Paris. The "Factories and Men" operation is being organised by 'Mouvement des entreprises de taille intermédiaire' (METI), an organisation which represents intermediate-sized businesses in France. The project began with a preview at the Petit Palais, and METI has organised a series of events which will take place until the end of 2015 with the aim of spotlighting the best of French industry. Thirty five businesses, including Virbac, are taking part. 

Since 2012, Virbac has maintained a presence in China through a commercial subsidiary that now has about thirty collaborators. How is the subsidiary adapting to this ever-changing market? Answers by the subsidiary general manager.

Growth of half-year results

On March 8, 2016, Virbac US announced the launch of the latest advancement in canine joint health supplementation, MOVOFLEX™ Soft Chews. Formulated with a unique and proprietary blend of ingredients, MOVOFLEX™ Soft Chews provide comprehensive canine joint support in a once-a-day palatable soft chew.

Virbac announces the appointment of Marie-Paule Porte as Group general counsel. Member of the strategic committee and the Comex France, in charge of legal matters at a global level, she provides support to the executive board and area directors in relation to strategic decisions they take.

In its 2015 report, Virbac adopted the most recent version of the GRI standard for sustainable development. The reasons behind this change and the related benefits explained by Éric Marée, chairman of the executive board.

Sales growth by 3.6% at constant exchange rates in the first half

Virbac announces the appointment of Habib Ramdani as chief financial officer. Appointed to the executive board on June 23, 2016, Habib has overseen all financial activities of the Group since taking office on May 2, 2016, reporting directly to Éric Marée, chairman of the Virbac group executive board.

Virbac announces the appointment of Andres Engelbreit as Latin American area director as of January 1, 2016. In conjunction with the business development, innovation and global marketing teams, Andres Engelbreit’s missions are to increase the Virbac’s market share in Latin America and improve its profitability in the area in a lasting way. He has been a development director in the area since 2012.

On March 1, 2016, Virbac US announced the launch of the C.E.T.^® OraStrip^® Dental Diagnostic Test (currently distributed in the USA), the first and only test in the animal health market that detects periodontal infection in dogs, providing visual test results to support veterinarians’ dental treatment recommendations and enhance client compliance.

Virbac has been distributing the parasiticide medicines Activyl^® and Activyl^® Tick Plus in Europe since January 1, 2016. The integration of these two medicines in the parasiticide product portfolio fulfils Virbac’s wish to offer complementary solutions to veterinarians.

Sales in the first quarter 2016 : return to organic growth

Virbac is investing $37.9 millions in its production site in Bridgeton, Missouri.

A 3,600 m² space dedicated to production! At the end of September the new Instrucciones site was opened in Uruguay, with a special emphasis on quality. An introduction to this leading edge facility by the subsidiary’s general manager.

2015 annual results heavily impacted by the United States

“Shaping the future of animal health”. This is now Virbac's new tagline, replacing “Passionate about animal health”, launched in 2001.
What message does this new slogan convey? Answers from Sandrine Brunel, head of Corporate Communications.

Virbac commercializes a new hyper premium nutritional concept for dogs and cats! 

At the beginning of October the GMBO (Global Marketing) organized the first Virbac Dairy Symposium in France, attended by experts from the dairy sector and Virbac staff from all over the world. Fabrice Payot, Global Marketing manager on the dairy cattle segment, explains the objectives of this major event. 

26%. This is 2014 Virbac Colombia's market share on the dog and cat vaccines segment. This figure is evidence of the success that the subsidiary has met with in this fast-growing sector. The story of a lightningfast journey by colombian Marketing manager.

As well as gender equality, age equality, now it's the turn of disability.
As part of its diversity policy in France, at the end of 2014 Virbac signed an agreement with its social partners on this important theme within the company. Details of the content of this agreement with the diversity manager for France.

Annual sales growth of 10.2%, driven by exchange rates and acquisitions

New premises, dairy crisis, market concentration... 2015 is marking a turning point for the subsidiary in New Zealand. How are such evolutions to be tackled? Answers from general manager of the subsidiary.

Virbac announces the appointment of Jules Minke as Group biological Research and Development director. Jules Minke’s main task going forward is to coordinate and supervise all R&D activities and global teams involved in Virbac’s biological projects. He will also monitor regulatory activities in this area.

Virbac : sales grow by 5.5% in the third quarter

Half-year results  heavily impacted by the United States

Virbac announced that Dr. Steven Buchholz has been appointed to the position of vice president, Quality & Compliance of Virbac U.S.

Virbac has announced the appointment of Francesca Cortella as head of its group Human Resources department. Francesca Cortella will join the Strategic Committee and Executive Committee for France. 

Virbac : sales grow by 18.1% in the first half

November 2014, London. For its use of augmented reality technology Virbac UK is awarded the Best Large Stand award for the most innovative stand. Just a gadget or a genuine opportunity for improved communication? Some answers from the companion animal business unit director of the subsidiary.

Group’s perspectives for 2015 impacted by the industrial situation in the United-States

Sales growth of 17.1% in the first quarter